News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
New Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN
HUTCHMED (00013.HK) and INNOVENT BIO (01801.HK) jointly announced that their new drug application for the combination therapy of fruquintinib and sintilimab has been accepted by Ch...
Reset
Send
The window will close in 5 seconds
New Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN
Close
Recommend
16
Positive
15
Negative
13
 
SHORT SELL
 
STOCK INFO

HUTCHMED (00013.HK)  0.000 (0.000%)    Short selling $25.31M; Ratio 9.024%   and INNOVENT BIO (01801.HK)  0.000 (0.000%)    Short selling $52.41M; Ratio 5.626%   jointly announced that their new drug application for the combination therapy of fruquintinib and sintilimab has been accepted by China's National Medical Products Administration.

This therapy is intended for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-21 16:25.)

Related NewsJPM Favors AKESO/ INNOVENT BIO/ HENGRUI PHARMA as CN Healthcare Sector Rebounds Sharply This Yr

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.